## FORM 4

Check this box if no longer subje Section 16. Form 4 or Form 5

obligations may continue. See Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D	D.C. 20549
---------------	------------

ct to	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number:

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Sec	curities Exchange Act of 1934
or Section 30(h) of the Investment	Company Act of 1940

1. Name and Address of Reporting Person*  Peters Jeffrey J					2. Issuer Name <b>and</b> Ticker or Trading Symbol  Xtant Medical Holdings, Inc. [XTNT]											ationship of Reportin (all applicable) Director Officer (give title below)		g Person(s) to Issue 10% Own Other (spe below)		
(Last)	Last) (First) (Middle)			3. Date of Earliest Transaction (Month/Day/Year) 02/05/2020																
(Street) BELGRADE MT 59714  (City) (State) (Zip)				4. If <i>i</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)									Indivi ne) X	dual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person					
		Tabl	e I - No	n-Deriv	ative	Sec	uritie	s Acc	quired,	Dis	posed o	f, or	Bene	eficia	ally (	Owne	ed			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					Execution Date,			3. 4. Securities Acquired Disposed Of (D) (Instr. 8)					nd	5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount		(A) or (D)	Price	.	Transaction(s) (Instr. 3 and 4)				(11311. 4)
Common Stock, \$0.000001 par value 0				02/05/	5/2020				A		116,197	7 <sup>(1)</sup> A		\$	\$0 1		147,794 <sup>(2)</sup>		D	
		Та									sed of, onvertib				y Ow	ned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	n Date, ay/Year)	Code (In	ransaction of ode (Instr. Deriv		ative rities ired osed	6. Date Expiration (Month/D	n Dat	е	7. Title and Amount of Securities Underlying Derivative Security (Instrand 4)  Amou or Numb of Title		ount	8. Pri Deriv Secu (Instr	ative rity	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	O F D oi (i)	0. bwnership orm: birect (D) r Indirect ) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

## **Explanation of Responses:**

1. These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, and will vest and become issuable with respect 58,098 shares on February 15, 2021 and with respect to 58,099 shares on February 15, 2022, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

/s/ Amy Culbert, attorney-in-

fact

\*\* Signature of Reporting Person

02/07/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>2.</sup> Includes (i) 116,197 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, conditioned upon the reporting person remaining a director of Xtant through the vesting date; (ii) 5,555 shares to be issued upon vesting pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, conditioned upon the reporting person remaining a director of Xtant through the vesting date, and (iii) 13,021 shares issued as part of a restricted stock award granted under the Amended and Restated Xtant Equity Incentive Plan, which shares are subject to forfeiture until vested.